
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is a commercial-stage biopharmaceutical company with a strong focus on developing innovative precision medicines for the treatment of immuno-oncology, autoimmune disorders, and infectious diseases. The company has a diverse pipeline of products, including Papzimeos, which has shown promising results in clinical trials and is expected to be a franchise product for the company. Additionally, Precigen has filed for a Marketing Authorization Application with the EMA and is planning to expand the drug's indications to the pediatric population. Financially, Precigen has reported a strong 4Q25 with sales of $3.4M and a net loss of $0.04 per diluted share. The company is expected to see rapid growth in 1Q26 with sales expected to exceed $18M. Furthermore, with sufficient cash reserves and potential growth from Papzimeos, Precigen has the financial means to continue its research and development programs, including the promising PRGN-2009. Overall, the company's portfolio, growth potential, and strong financial position make it a favorable investment opportunity for long-term growth.
Bears say
Precigen is expected to have strong sales for Papzimeos in 1Q26 due to a significant increase in product sales, driven by higher-than-expected adoption and a favorable reimbursement environment. However, there are risks associated with clinical, regulatory, commercial, partnership, financial, and intellectual property factors that could impact the company's performance and the price of its stock in the long-term. While the company's stock price may receive a temporary boost, due to an increase in price target from $9 to $10, these risks should be considered carefully before making any investment decisions.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares